Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Wakamoto Pharmaceutical Co's quarterly finished goods
increased
from Mar. 2025 (円1,964 Mil) to Sep. 2025 (円2,190 Mil) and
increased
from Sep. 2025 (円2,190 Mil) to Mar. 2026 (円2,619 Mil).
Wakamoto Pharmaceutical Co's annual finished goods
increased
from Mar. 2024 (円1,031 Mil) to Mar. 2025 (円1,964 Mil) and
increased
from Mar. 2025 (円1,964 Mil) to Mar. 2026 (円2,619 Mil).
Wakamoto Pharmaceutical Co Inventories, Finished Goods Historical Data
* Premium members only.
The historical data trend for Wakamoto Pharmaceutical Co's Inventories, Finished Goods can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wakamoto Pharmaceutical Co Inventories, Finished Goods Chart
What does a Inventories, Finished Goods of 円2,619 Mil mean?
Wakamoto Pharmaceutical Co (TSE:4512) has a Inventories, Finished Goods of 円2,619 Mil as of Mar. 2026. Finished goods are inventory items that are complete and ready to be sold. View historical data on Wakamoto Pharmaceutical Co and its competitors.
Is Wakamoto Pharmaceutical Co's Inventories, Finished Goods too high?
Wakamoto Pharmaceutical Co's current Inventories, Finished Goods is 円2,619 Mil. Overall, Wakamoto Pharmaceutical Co has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Wakamoto Pharmaceutical Co's Inventories, Finished Goods compare to ZTS and UTHR?
Wakamoto Pharmaceutical Co's Inventories, Finished Goods of 円2,619 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Finished Goods for a Drug Manufacturers company?
A good Inventories, Finished Goods depends on the Drug Manufacturers industry context. However, Inventories, Finished Goods should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Finished Goods mean?
A high Inventories, Finished Goods can signal that a stock is expensive relative to its fundamentals. Finished goods are inventory items that are complete and ready to be sold. View historical data on Wakamoto Pharmaceutical Co and its competitors. Wakamoto Pharmaceutical Co's current Inventories, Finished Goods is 円2,619 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wakamoto Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Wakamoto Pharmaceutical Co (TSE:4512) is currently considered Modestly Undervalued. The stock's GF Value™ is 円319.46, compared to a current price of 円274.00 — trading 14.2% below its estimated fair value. The current Inventories, Finished Goods is 円2,619 Mil. Wakamoto Pharmaceutical Co's overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Finished Goods calculated?
Inventories, Finished Goods is calculated from a company's financial statements. For Wakamoto Pharmaceutical Co (TSE:4512), the current Inventories, Finished Goods is 円2,619 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wakamoto Pharmaceutical Co (TSE:4512) Overvalued in 2026?
Based on GuruFocus' analysis, Wakamoto Pharmaceutical Co stock appears to be undervalued.
The current stock price of 円274.00 is trading 14.2% below its estimated GF Value™ of 円319.46.
GuruFocus considers Wakamoto Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for TSE:4512:
Inventories, Finished Goods: 円2,619 Mil
GF Value™: 円319.46 vs. price of 円274.00 (14.2% below fair value)
No single metric tells the full story. See the TSE:4512 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Wakamoto Pharmaceutical Co Ltd is the pharmaceutical company based in Japan. It is engaged in the research and development, production and sale of ethical drugs and non-prescription drugs. The company specializes in therapeutic and diagnostic agents for ophthalmic disorders. It offers Strong Wakamoto, a gastrointestinal drug for digestion, the intestinal function controlling, and nutritional supply.
62GF Score
Get the complete analysis for TSE:4512
Inventories, Finished Goods is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4512 has been successfully added to your 
